Jam

Rocket Lab successfully launched its 68th Electron rocket mission, deploying a satellite for a commercial customer. The “Symphony In The Stars” launch, from New Zealand, set a company record for rapid turnaround. This mission is the first of two for the customer, demonstrating Electron’s reliability and Rocket Lab’s commitment to consistent space access. This is the tenth successful Electron mission of the year, solidifying its position as leader in small satellite launches.

S&P Global Ratings downgraded Ecopetrol’s global credit rating to BB from BB+, mirroring Colombia’s sovereign rating cut. The outlook remains negative. Despite the downgrade, Ecopetrol’s Stand-Alone Credit Profile was affirmed at bb+. S&P cited Ecopetrol’s importance to national revenue and its role in the nation’s energy transition. The agency expects a leverage ratio between 2.0x and 2.5x and a 40% EBITDA margin. Ecopetrol’s 2040 strategy focusing on growth and diversification was also highlighted.

Reyna Silver Corp. completed a $1.1 million non-brokered private placement, linked to Torex Gold Resources Inc.’s acquisition of Reyna. The placement, priced at $0.095 per unit, includes warrants exercisable at $0.13. Proceeds will fund option agreement payments and exploration in Nevada. Completion is contingent on TSXV approval, with securities subject to a four-month hold period. Reyna Silver focuses on high-grade silver deposits in North America, including projects in Nevada and Mexico.

United Lithium Corp. announced the results of its annual general meeting held on June 27, 2025, with strong shareholder support. All director nominees were successfully elected with over 93% votes in favor. Shareholders also reappointed the company’s auditor. The meeting saw 4,789,956 shares represented, highlighting investor confidence in United Lithium’s strategy.

Jayden Resources Inc. (JDN) secured a $250,000 loan to support operations, with repayment due in one year or upon a private placement. The loan has a 10% annual interest rate and is subject to TSX Venture Exchange approval, earmarked for working capital. The announcement includes forward-looking statements and cautions about potential risks.

Ascent Solar Technologies is offering 1,000,000 shares of common stock or pre-funded warrants, alongside warrants for another 1,000,000 shares, priced at $2.00 per share. The offering, led by H.C. Wainwright & Co., aims to raise $2 million, with an anticipated close by June 30, 2025. Proceeds will fund working capital, product development, and general expenses. The company’s focus is on high-performance flexible solar panels for various applications.

Shell plc announced the repurchase of a significant number of its own shares on June 27, 2025, as part of its capital management strategy. The announcement details the aggregated share repurchase transactions, including the number of shares purchased, prices paid, venue, and currency. This is part of a buy-back program initiated in May 2025.

Biogen released positive new data on its SMA treatment, SPINRAZA (nusinersen). Findings from the DEVOTE and NURTURE trials highlight the drug’s continued efficacy. The DEVOTE data suggests potential benefits from a higher dose regimen for previously treated patients, showing functional improvements across different patient groups. The final NURTURE study results reinforce the value of early intervention, demonstrating long-term benefits and safety. Biogen is awaiting regulatory approvals for the new higher dose regimen.

OFA Group (Nasdaq: OFAL) plans to acquire a 60% stake in Aspire Homes Realty and RateDNA, a real estate and lending platform, to expand its revenue streams. This strategic move aims to leverage the acquired team’s expertise and drive growth in residential real estate and specialty lending markets. The acquisition, expected to offer integrated services and investor-focused mortgage products, is subject to risks outlined in forward-looking statements.

IDEAYA Biosciences announced stock option grants to a new employee. The company awarded 95,600 shares at $22.29 per share under its 2023 plan, aiming to attract talent. Options vest over four years, with 25% vesting after the first year. IDEAYA, a precision medicine oncology company, focuses on targeted therapies based on molecular diagnostics and synthetic lethality approaches.